HONG KONG – An affordable anti-microbial drug used to treat stomach ulcers and bacterial infections has shown promise in fighting the novel coronavirus in animals, scientists in Hong Kong announced yesterday.
Researchers set out to explore whether metallodrugs – compounds containing metal that are more commonly used against bacteria – might also have anti-viral properties that could fight the SARS-CoV-2 coronavirus.
Using golden hamsters as tests subjects, they found that one of the drugs, ranitidine bismuth citrate (RBC), is “a potent anti-SARS-CoV-2 agent”.
“RBC is able to lower the viral load in the lung of the infected hamster by tenfold,” Hong Kong University researcher Wang Runming told reporters yesterday as the team presented their study.
“Our findings demonstrate that RBC is a potential anti-viral agent for COVID-19.”
As scientists scramble to find a vaccine, they have also been scouring readily available drugs that might alleviate symptoms caused by COVID-19 or help the body fight infection.
Remdesivir, a broad-spectrum antiviral drug, and dexamethasone, a type of corticosteroid, have both been identified as having some success against the virus. Both were used by doctors to treat US President Donald Trump after he contracted COVID-19.
But they have drawbacks.
Remdesivir is expensive and there is a global shortage while dexamethasone has immunosuppression effects that are risky for all but the most ill patients. Other drug cocktails have shown liver damage can be a risk.
The Hong Kong scientists said RBC was a commonly available drug used against stomach ulcers with a safe and comprehensive pharmacological profile.
“It’s been used for decades so it’s pretty safe,” Wang said.
They added that their research, which has been published in the journal Nature Microbiology, suggested other metallodrugs might also have success against the virus and should be further explored. – AFP, MPD
